25 XP   0   0   10

Bioventus Inc
Buy, Hold or Sell?

Let's analyse Bioventus together

PenkeI guess you are interested in Bioventus Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Bioventus Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Bioventus Inc

I send you an email if I find something interesting about Bioventus Inc.

Quick analysis of Bioventus (30 sec.)










What can you expect buying and holding a share of Bioventus? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
47.4%

What is your share worth?

Current worth
$3.49
Expected worth in 1 year
$1.61
How sure are you?
47.4%

+ What do you gain per year?

Total Gains per Share
$-1.88
Return On Investment
-42.0%

For what price can you sell your share?

Current Price per Share
$4.48
Expected price per share
$4.28 - $5.85
How sure are you?
50%

1. Valuation of Bioventus (5 min.)




Live pricePrice per Share (EOD)

$4.48

Intrinsic Value Per Share

$2.07 - $2.50

Total Value Per Share

$5.56 - $5.99

2. Growth of Bioventus (5 min.)




Is Bioventus growing?

Current yearPrevious yearGrowGrow %
How rich?$221.1m$477.6m-$247.2m-107.4%

How much money is Bioventus making?

Current yearPrevious yearGrowGrow %
Making money-$29.2m-$16.1m-$13.1m-44.9%
Net Profit Margin-24.3%-12.9%--

How much money comes from the company's main activities?

3. Financial Health of Bioventus (5 min.)




4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#98 / 339

Most Revenue
#73 / 339

Most Profit
#307 / 339

Most Efficient
#186 / 339

What can you expect buying and holding a share of Bioventus? (5 min.)

Welcome investor! Bioventus's management wants to use your money to grow the business. In return you get a share of Bioventus.

What can you expect buying and holding a share of Bioventus?

First you should know what it really means to hold a share of Bioventus. And how you can make/lose money.

Speculation

The Price per Share of Bioventus is $4.48. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bioventus.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bioventus, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.49. Based on the TTM, the Book Value Change Per Share is $-0.47 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.76 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bioventus.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.10-2.1%-0.62-13.8%-0.62-13.7%-0.26-5.9%-0.26-5.8%
Usd Book Value Change Per Share-0.08-1.9%-0.47-10.5%-0.76-17.0%0.030.7%0.184.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.030.7%0.030.6%
Usd Total Gains Per Share-0.08-1.9%-0.47-10.5%-0.76-17.0%0.061.4%0.214.7%
Usd Price Per Share5.27-3.13-7.63-6.15-5.50-
Price to Earnings Ratio-13.70--8.35-7.06--53.14--47.54-
Price-to-Total Gains Ratio-62.57--29.93--67.41--131.03--131.03-
Price to Book Ratio1.51-0.88-0.97-1.32-1.18-
Price-to-Total Gains Ratio-62.57--29.93--67.41--131.03--131.03-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.48
Number of shares223
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.03
Usd Book Value Change Per Share-0.470.03
Usd Total Gains Per Share-0.470.06
Gains per Quarter (223 shares)-104.8613.75
Gains per Year (223 shares)-419.4655.00
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-419-429262945
20-839-8485258100
30-1258-12677986155
40-1678-1686105115210
50-2097-2105131144265
60-2517-2524157173320
70-2936-2943183202375
80-3356-3362209231430
90-3775-3781236259485
100-4195-4200262288540

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%2.010.00.016.7%6.011.00.035.3%6.013.00.031.6%6.013.00.031.6%
Book Value Change Per Share0.04.00.00.0%4.08.00.033.3%4.011.02.023.5%5.011.03.026.3%5.011.03.026.3%
Dividend per Share0.00.04.00.0%4.00.08.033.3%9.00.08.052.9%9.00.010.047.4%9.00.010.047.4%
Total Gains per Share0.04.00.00.0%4.08.00.033.3%8.09.00.047.1%9.09.01.047.4%9.09.01.047.4%

Fundamentals of Bioventus

About Bioventus Inc

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Fundamental data was last updated by Penke on 2024-04-11 03:07:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Bioventus Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Bioventus earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • A Net Profit Margin of -4.5% means that $-0.05 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Bioventus Inc:

  • The MRQ is -4.5%. The company is making a loss. -1
  • The TTM is -24.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-4.5%TTM-24.3%+19.8%
TTM-24.3%YOY-12.9%-11.4%
TTM-24.3%5Y-5.9%-18.4%
5Y-5.9%10Y-7.9%+1.9%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.5%-11.2%+6.7%
TTM-24.3%-19.6%-4.7%
YOY-12.9%-14.4%+1.5%
5Y-5.9%-21.3%+15.4%
10Y-7.9%-24.8%+16.9%
1.1.2. Return on Assets

Shows how efficient Bioventus is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • -0.8% Return on Assets means that Bioventus generated $-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Bioventus Inc:

  • The MRQ is -0.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.8%TTM-3.3%+2.6%
TTM-3.3%YOY-1.2%-2.1%
TTM-3.3%5Y-0.6%-2.7%
5Y-0.6%10Y-0.6%0.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.8%-4.0%+3.2%
TTM-3.3%-4.5%+1.2%
YOY-1.2%-4.8%+3.6%
5Y-0.6%-4.0%+3.4%
10Y-0.6%-4.9%+4.3%
1.1.3. Return on Equity

Shows how efficient Bioventus is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • -3.5% Return on Equity means Bioventus generated $-0.04 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Bioventus Inc:

  • The MRQ is -3.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -15.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.5%TTM-15.7%+12.2%
TTM-15.7%YOY-4.6%-11.0%
TTM-15.7%5Y-3.1%-12.6%
5Y-3.1%10Y-2.9%-0.2%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.5%-3.9%+0.4%
TTM-15.7%-5.6%-10.1%
YOY-4.6%-5.9%+1.3%
5Y-3.1%-6.1%+3.0%
10Y-2.9%-7.0%+4.1%

1.2. Operating Efficiency of Bioventus Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Bioventus is operating .

  • Measures how much profit Bioventus makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • An Operating Margin of 3.1% means the company generated $0.03  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Bioventus Inc:

  • The MRQ is 3.1%. The company is operating less efficient.
  • The TTM is 16.9%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ3.1%TTM16.9%-13.7%
TTM16.9%YOY-5.0%+21.9%
TTM16.9%5Y7.0%+9.8%
5Y7.0%10Y5.6%+1.4%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1%-24.1%+27.2%
TTM16.9%-16.9%+33.8%
YOY-5.0%-13.4%+8.4%
5Y7.0%-19.2%+26.2%
10Y5.6%-24.0%+29.6%
1.2.2. Operating Ratio

Measures how efficient Bioventus is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 0.97 means that the operating costs are $0.97 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Bioventus Inc:

  • The MRQ is 0.969. The company is less efficient in keeping operating costs low.
  • The TTM is 0.996. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.969TTM0.996-0.027
TTM0.996YOY1.095-0.099
TTM0.9965Y0.984+0.012
5Y0.98410Y0.992-0.008
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9691.431-0.462
TTM0.9961.426-0.430
YOY1.0951.503-0.408
5Y0.9841.440-0.456
10Y0.9921.371-0.379

1.3. Liquidity of Bioventus Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Bioventus is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 1.53 means the company has $1.53 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Bioventus Inc:

  • The MRQ is 1.527. The company is able to pay all its short-term debts. +1
  • The TTM is 1.527. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.527TTM1.527+0.000
TTM1.527YOY1.167+0.359
TTM1.5275Y1.349+0.178
5Y1.34910Y1.267+0.081
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5272.754-1.227
TTM1.5272.763-1.236
YOY1.1673.488-2.321
5Y1.3493.617-2.268
10Y1.2673.514-2.247
1.3.2. Quick Ratio

Measures if Bioventus is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • A Quick Ratio of 0.91 means the company can pay off $0.91 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Bioventus Inc:

  • The MRQ is 0.912. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.864. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.912TTM0.864+0.047
TTM0.864YOY0.729+0.135
TTM0.8645Y0.959-0.095
5Y0.95910Y0.893+0.066
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9121.532-0.620
TTM0.8641.656-0.792
YOY0.7292.139-1.410
5Y0.9592.301-1.342
10Y0.8932.255-1.362

1.4. Solvency of Bioventus Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Bioventus assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bioventus to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.73 means that Bioventus assets are financed with 72.7% credit (debt) and the remaining percentage (100% - 72.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Bioventus Inc:

  • The MRQ is 0.727. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.725. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.727TTM0.725+0.003
TTM0.725YOY0.638+0.086
TTM0.7255Y0.674+0.050
5Y0.67410Y0.636+0.039
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7270.389+0.338
TTM0.7250.386+0.339
YOY0.6380.338+0.300
5Y0.6740.442+0.232
10Y0.6360.460+0.176
1.4.2. Debt to Equity Ratio

Measures if Bioventus is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • A Debt to Equity ratio of 339.8% means that company has $3.40 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Bioventus Inc:

  • The MRQ is 3.398. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.355. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ3.398TTM3.355+0.043
TTM3.355YOY2.159+1.196
TTM3.3555Y2.587+0.767
5Y2.58710Y2.400+0.188
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3980.559+2.839
TTM3.3550.560+2.795
YOY2.1590.478+1.681
5Y2.5870.624+1.963
10Y2.4000.674+1.726

2. Market Valuation of Bioventus Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Bioventus generates.

  • Above 15 is considered overpriced but always compare Bioventus to the Medical Devices industry mean.
  • A PE ratio of -13.70 means the investor is paying $-13.70 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Bioventus Inc:

  • The EOD is -11.644. Based on the earnings, the company is expensive. -2
  • The MRQ is -13.698. Based on the earnings, the company is expensive. -2
  • The TTM is -8.355. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.644MRQ-13.698+2.053
MRQ-13.698TTM-8.355-5.343
TTM-8.355YOY7.056-15.411
TTM-8.3555Y-53.135+44.781
5Y-53.13510Y-47.542-5.593
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-11.644-0.997-10.647
MRQ-13.698-1.578-12.120
TTM-8.355-2.041-6.314
YOY7.056-2.761+9.817
5Y-53.135-2.064-51.071
10Y-47.542-1.463-46.079
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Bioventus Inc:

  • The EOD is 7.095. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 8.346. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -1.919. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD7.095MRQ8.346-1.251
MRQ8.346TTM-1.919+10.265
TTM-1.919YOY21.342-23.262
TTM-1.9195Y7.691-9.611
5Y7.69110Y6.882+0.810
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD7.095-0.935+8.030
MRQ8.346-1.489+9.835
TTM-1.919-2.994+1.075
YOY21.342-6.238+27.580
5Y7.691-4.771+12.462
10Y6.882-4.736+11.618
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Bioventus is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 1.51 means the investor is paying $1.51 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Bioventus Inc:

  • The EOD is 1.284. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.511. Based on the equity, the company is underpriced. +1
  • The TTM is 0.875. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.284MRQ1.511-0.226
MRQ1.511TTM0.875+0.635
TTM0.875YOY0.967-0.092
TTM0.8755Y1.322-0.446
5Y1.32210Y1.182+0.139
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD1.2841.890-0.606
MRQ1.5112.379-0.868
TTM0.8752.458-1.583
YOY0.9673.214-2.247
5Y1.3223.833-2.511
10Y1.1824.173-2.991
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Bioventus Inc.

3.1. Institutions holding Bioventus Inc

Institutions are holding 66.296% of the shares of Bioventus Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Essex Woodlands Health Ventures16.448216.98171302132400
2023-12-31Nantahala Capital Management, LLC15.10121.884411954942593641098.6355
2023-09-30Juniper Investment Co, LLC8.632414.316268338571768702.6569
2023-12-31Vanguard Group Inc1.53920.00011218500174201.4504
2023-12-31Kent Lake Capital LLC0.67311.0845532880-502288-48.5224
2023-12-31BlackRock Inc0.63860.0001505574-1460-0.2879
2023-12-31Geode Capital Management, LLC0.51470.0002407444227425.9116
2023-09-30Jacobs Levy Equity Management, Inc.0.46260.0072366183300450457.0764
2023-12-31Bridgeway Capital Management, LLC0.45950.041136380400
2023-12-31Susquehanna International Group, LLP0.3230.00032557267406440.7702
2023-12-31Millennium Management LLC0.29750.0005235483-104693-30.7761
2023-12-31Morgan Stanley - Brokerage Accounts0.24450.00011935291828751716.4915
2023-12-31Marshall Wace Asset Management Ltd0.24080.0017190635-74314-28.0484
2023-12-31Charles Schwab Investment Management Inc0.22810.000218054631981.8032
2023-12-31Qube Research & Technologies0.22540.0018178459154936658.6575
2023-12-31JANE STREET GROUP, LLC0.19660.0002155650124401398.0959
2023-12-31Stephens Inc0.18020.013142675-8800-5.8095
2023-12-31Renaissance Technologies Corp0.17080.00111352455544569.4799
2023-12-31Mariner Wealth Advisors, LLC0.1650.00161305865464271.9504
2023-12-31Two Sigma Advisers, LLC0.16160.001612793278400158.2815
Total 46.90334.337637130974+6490298+17.5%

3.2. Funds holding Bioventus Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv0.85780.000267910300
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.61690.002248838500
2023-12-31Bridgeway Omni Small-Cap Value0.28420.092322500000
2023-12-31Bridgeway Omni Small-Cap Value N0.28420.092522500000
2024-02-29Fidelity Extended Market Index0.2280.0022180496-875-0.4824
2024-03-29Schwab US Small-Cap ETF™0.1890.004614960100
2023-12-31Bridgeway Ultra-Small Company Market0.16420.368713000000
2024-02-29SEI Tax-Managed Small/Mid Cap F (SIMT)0.16350.070512944086387.1505
2023-09-30BlackRock Extended Mkt Composite0.11860.0022939254660998.5058
2024-03-31BlackRock Extended Equity Market K0.10350.002981971300.0366
2023-12-31Kennedy Micro Cap Opportunities0.08990.72867115145956.904
2024-03-28iShares Micro-Cap ETF0.08910.03997054217642.5648
2024-03-27Fidelity Nasdaq Composite ETF0.07740.00526126600
2023-12-31Bailard Micrcap Value0.07351.163958202582020
2023-12-31Bailard Small Cap Value0.07350.303558202582020
2024-02-29Fidelity Total Market Index0.07270.00035758300
2024-02-29SEI Small Cap F (SIMT)0.07230.044257198-52802-48.0018
2024-02-29Nationwide Bailard Cogntv Val M0.07030.25875567745008.793
2024-02-29Fidelity Series Total Market Index0.05710.000345168-978-2.1194
2024-02-29MFS Blended Research Small Cap Eq R60.05510.0624359600
Total 3.74083.24492961506+127885+4.3%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Bioventus Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.084-0.470+458%-0.763+806%0.032-361%0.184-146%
Book Value Per Share--3.4893.634-4%7.536-54%4.420-21%4.109-15%
Current Ratio--1.5271.527+0%1.167+31%1.349+13%1.267+21%
Debt To Asset Ratio--0.7270.725+0%0.638+14%0.674+8%0.636+14%
Debt To Equity Ratio--3.3983.355+1%2.159+57%2.587+31%2.400+42%
Dividend Per Share----0%-0%0.029-100%0.026-100%
Eps---0.096-0.616+541%-0.615+539%-0.264+174%-0.258+169%
Free Cash Flow Per Share--0.1580.031+401%-0.099+163%0.065+142%0.051+209%
Free Cash Flow To Equity Per Share--0.158-0.074+147%0.146+8%0.325-51%0.291-46%
Gross Profit Margin--1.0001.0000%1.029-3%1.007-1%1.006-1%
Intrinsic Value_10Y_max--2.501--------
Intrinsic Value_10Y_min--2.073--------
Intrinsic Value_1Y_max--0.030--------
Intrinsic Value_1Y_min--0.029--------
Intrinsic Value_3Y_max--0.258--------
Intrinsic Value_3Y_min--0.243--------
Intrinsic Value_5Y_max--0.689--------
Intrinsic Value_5Y_min--0.625--------
Market Cap283937024.000-18%334006276.000198534091.000+68%483738691.000-31%389928746.588-14%348883615.368-4%
Net Profit Margin---0.045-0.243+440%-0.129+187%-0.059+32%-0.079+75%
Operating Margin--0.0310.169-81%-0.050+261%0.070-55%0.056-44%
Operating Ratio--0.9690.996-3%1.095-12%0.984-2%0.992-2%
Pb Ratio1.284-18%1.5110.875+73%0.967+56%1.322+14%1.182+28%
Pe Ratio-11.644+15%-13.698-8.355-39%7.056-294%-53.135+288%-47.542+247%
Price Per Share4.480-18%5.2703.133+68%7.633-31%6.152-14%5.505-4%
Price To Free Cash Flow Ratio7.095-18%8.346-1.919+123%21.342-61%7.691+9%6.882+21%
Price To Total Gains Ratio-53.192+15%-62.571-29.929-52%-67.408+8%-131.028+109%-131.028+109%
Quick Ratio--0.9120.864+5%0.729+25%0.959-5%0.893+2%
Return On Assets---0.008-0.033+344%-0.012+65%-0.006-17%-0.006-17%
Return On Equity---0.035-0.157+346%-0.046+32%-0.031-13%-0.029-17%
Total Gains Per Share---0.084-0.470+458%-0.763+806%0.062-237%0.210-140%
Usd Book Value--221118000.000230319250.000-4%477614750.000-54%280118705.882-21%260437894.737-15%
Usd Book Value Change Per Share---0.084-0.470+458%-0.763+806%0.032-361%0.184-146%
Usd Book Value Per Share--3.4893.634-4%7.536-54%4.420-21%4.109-15%
Usd Dividend Per Share----0%-0%0.029-100%0.026-100%
Usd Eps---0.096-0.616+541%-0.615+539%-0.264+174%-0.258+169%
Usd Free Cash Flow--10005000.0001995500.000+401%-6264250.000+163%4126823.529+142%3239631.579+209%
Usd Free Cash Flow Per Share--0.1580.031+401%-0.099+163%0.065+142%0.051+209%
Usd Free Cash Flow To Equity Per Share--0.158-0.074+147%0.146+8%0.325-51%0.291-46%
Usd Market Cap283937024.000-18%334006276.000198534091.000+68%483738691.000-31%389928746.588-14%348883615.368-4%
Usd Price Per Share4.480-18%5.2703.133+68%7.633-31%6.152-14%5.505-4%
Usd Profit---6096000.000-29274500.000+380%-16129500.000+165%-8246647.059+35%-8803157.895+44%
Usd Revenue--135423000.000128086250.000+6%130131500.000+4%110734352.941+22%105328842.105+29%
Usd Total Gains Per Share---0.084-0.470+458%-0.763+806%0.062-237%0.210-140%
 EOD+4 -4MRQTTM+23 -10YOY+24 -105Y+12 -2410Y+13 -23

4.2. Fundamental Score

Let's check the fundamental score of Bioventus Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-11.644
Price to Book Ratio (EOD)Between0-11.284
Net Profit Margin (MRQ)Greater than0-0.045
Operating Margin (MRQ)Greater than00.031
Quick Ratio (MRQ)Greater than10.912
Current Ratio (MRQ)Greater than11.527
Debt to Asset Ratio (MRQ)Less than10.727
Debt to Equity Ratio (MRQ)Less than13.398
Return on Equity (MRQ)Greater than0.15-0.035
Return on Assets (MRQ)Greater than0.05-0.008
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Bioventus Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose4.550
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets810,910
Total Liabilities589,792
Total Stockholder Equity173,591
 As reported
Total Liabilities 589,792
Total Stockholder Equity+ 173,591
Total Assets = 810,910

Assets

Total Assets810,910
Total Current Assets267,999
Long-term Assets542,911
Total Current Assets
Cash And Cash Equivalents 36,964
Net Receivables 123,046
Inventory 91,333
Other Current Assets 16,656
Total Current Assets  (as reported)267,999
Total Current Assets  (calculated)267,999
+/-0
Long-term Assets
Property Plant Equipment 49,958
Goodwill 7,462
Intangible Assets 482,350
Long-term Assets Other 3,141
Long-term Assets  (as reported)542,911
Long-term Assets  (calculated)542,911
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities175,497
Long-term Liabilities414,295
Total Stockholder Equity173,591
Total Current Liabilities
Short-term Debt 31,905
Short Long Term Debt 27,848
Accounts payable 23,038
Other Current Liabilities 115,805
Total Current Liabilities  (as reported)175,497
Total Current Liabilities  (calculated)198,596
+/- 23,099
Long-term Liabilities
Long term Debt 366,998
Long-term Liabilities Other 46,084
Long-term Liabilities  (as reported)414,295
Long-term Liabilities  (calculated)413,082
+/- 1,213
Total Stockholder Equity
Common Stock79
Retained Earnings -321,536
Accumulated Other Comprehensive Income 794
Other Stockholders Equity 494,254
Total Stockholder Equity (as reported)173,591
Total Stockholder Equity (calculated)173,591
+/-0
Other
Capital Stock79
Cash and Short Term Investments 36,964
Common Stock Shares Outstanding 63,101
Current Deferred Revenue4,749
Liabilities and Stockholders Equity 810,910
Net Debt 372,512
Net Invested Capital 568,437
Net Working Capital 92,502
Property Plant and Equipment Gross 90,462
Short Long Term Debt Total 409,476



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312016-03-312015-03-31
> Total Assets 
0
486,264
472,407
0
0
479,277
494,466
643,075
646,636
654,790
1,225,862
1,197,137
1,208,776
1,587,220
1,372,649
887,404
836,962
811,104
810,910
810,910811,104836,962887,4041,372,6491,587,2201,208,7761,197,1371,225,862654,790646,636643,075494,466479,27700472,407486,2640
   > Total Current Assets 
0
99,985
183,033
0
0
193,141
211,794
270,721
290,060
246,078
263,103
245,395
277,157
271,082
272,575
308,664
260,638
249,452
267,999
267,999249,452260,638308,664272,575271,082277,157245,395263,103246,078290,060270,721211,794193,14100183,03399,9850
       Cash And Cash Equivalents 
0
6,166
64,520
0
0
72,478
86,839
124,247
136,065
80,917
43,933
27,374
41,001
34,359
31,814
47,102
29,389
26,827
36,964
36,96426,82729,38947,10231,81434,35941,00127,37443,93380,917136,065124,24786,83972,4780064,5206,1660
       Short-term Investments 
0
0
0
0
0
0
19,382
19,382
19,483
0
0
0
0
0
0
0
0
0
0
000000000019,48319,38219,382000000
       Net Receivables 
0
51,109
85,128
0
0
80,813
88,283
89,472
102,029
105,442
124,963
119,288
143,018
132,185
136,645
118,544
119,636
112,899
123,046
123,046112,899119,636118,544136,645132,185143,018119,288124,963105,442102,02989,47288,28380,8130085,12851,1090
       Other Current Assets 
0
5,591
6,059
0
0
5,145
7,552
11,987
15,943
23,154
27,239
34,042
24,060
27,586
18,685
17,192
11,113
10,033
16,656
16,65610,03311,11317,19218,68527,58624,06034,04227,23923,15415,94311,9877,5525,145006,0595,5910
   > Long-term Assets 
0
386,279
289,374
0
0
286,136
282,672
372,354
356,576
408,712
962,759
951,742
931,619
1,316,138
1,100,074
578,740
576,324
561,652
542,911
542,911561,652576,324578,7401,100,0741,316,138931,619951,742962,759408,712356,576372,354282,672286,13600289,374386,2790
       Property Plant Equipment 
0
8,984
19,756
0
0
19,792
21,840
26,144
26,629
27,235
40,171
43,594
43,454
42,947
44,955
52,619
57,100
54,002
49,958
49,95854,00257,10052,61944,95542,94743,45443,59440,17127,23526,62926,14421,84019,7920019,7568,9840
       Goodwill 
0
58,694
49,800
0
0
49,800
49,800
53,529
52,135
52,885
147,623
147,968
143,156
204,557
13,759
7,462
7,462
7,462
7,462
7,4627,4627,4627,46213,759204,557143,156147,968147,62352,88552,13553,52949,80049,8000049,80058,6940
       Long Term Investments 
0
0
0
0
0
19,856
19,382
21,158
19,483
29,317
29,291
28,811
78,486
13,033
2,636
2,620
0
0
0
0002,6202,63613,03378,48628,81129,29129,31719,48321,15819,38219,85600000
       Intangible Assets 
0
318,141
216,510
0
0
196,688
191,650
271,042
257,848
248,794
695,193
681,369
666,523
1,055,601
1,038,724
516,039
505,223
493,324
482,350
482,350493,324505,223516,0391,038,7241,055,601666,523681,369695,193248,794257,848271,042191,650196,68800216,510318,1410
       Other Assets 
0
0
0
0
0
0
34,343
481
481
50,481
50,481
50,000
0
0
0
0
0
0
0
000000050,00050,48150,48148148134,343000000
> Total Liabilities 
0
299,962
326,790
0
0
333,938
350,306
422,793
427,272
424,293
692,073
675,219
688,586
1,059,201
1,032,317
647,042
603,621
584,648
589,792
589,792584,648603,621647,0421,032,3171,059,201688,586675,219692,073424,293427,272422,793350,306333,93800326,790299,9620
   > Total Current Liabilities 
0
86,799
89,015
0
0
111,734
122,589
149,027
158,186
160,705
180,859
171,522
198,873
285,719
304,017
196,063
179,104
160,843
175,497
175,497160,843179,104196,063304,017285,719198,873171,522180,859160,705158,186149,027122,589111,7340089,01586,7990
       Short-term Debt 
0
39,290
10,000
0
0
16,250
15,000
15,000
15,000
15,000
18,038
20,292
22,547
31,302
33,056
41,320
11,320
19,584
31,905
31,90519,58411,32041,32033,05631,30222,54720,29218,03815,00015,00015,00015,00016,2500010,00039,2900
       Short Long Term Debt 
0
0
0
0
0
16,250
15,000
15,000
15,000
15,000
18,038
20,292
22,547
31,302
33,056
41,320
11,320
19,584
27,848
27,84819,58411,32041,32033,05631,30222,54720,29218,03815,00015,00015,00015,00016,25000000
       Accounts payable 
0
9,819
6,440
0
0
8,790
4,422
10,283
9,881
10,897
16,915
22,500
25,735
19,075
37,549
32,828
41,364
17,637
23,038
23,03817,63741,36432,82837,54919,07525,73522,50016,91510,8979,88110,2834,4228,790006,4409,8190
       Other Current Liabilities 
0
7,156
15,619
0
0
18,975
3,926
23,218
35,640
16,379
3,558
128,730
51,699
235,342
233,412
121,915
23,560
21,503
115,805
115,80521,50323,560121,915233,412235,34251,699128,7303,55816,37935,64023,2183,92618,9750015,6197,1560
   > Long-term Liabilities 
0
213,163
237,775
0
0
222,204
227,717
273,766
269,086
263,588
511,214
503,697
489,713
773,482
728,300
450,979
424,517
423,805
414,295
414,295423,805424,517450,979728,300773,482489,713503,697511,214263,588269,086273,766227,717222,20400237,775213,1630
       Long term Debt Total 
0
0
0
0
0
0
0
0
166,084
162,437
0
0
0
0
0
0
0
0
0
000000000162,437166,08400000000
       Other Liabilities 
0
0
35,297
0
0
31,996
40,231
87,633
103,002
101,151
171,570
139,443
138,280
380,380
0
46,714
37,460
0
0
0037,46046,7140380,380138,280139,443171,570101,151103,00287,63340,23131,9960035,29700
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
48,410
47,687
133,518
0
0
0
0
0
0
0
0
00000000133,51847,68748,41000000000
> Total Stockholder Equity
0
186,302
142,982
0
0
143,219
142,241
142,390
141,557
152,503
458,924
449,776
447,981
453,396
316,581
188,511
183,195
177,529
173,591
173,591177,529183,195188,511316,581453,396447,981449,776458,924152,503141,557142,390142,241143,21900142,982186,3020
   Common Stock
0
0
285,147
0
0
285,173
285,173
57
57
57
75
78
80
80
78
79
79
79
79
797979797880807875575757285,173285,17300285,14700
   Retained Earnings Total Equity00-308,137-304,4560-133,376-25,131-17,879-6,602-6,238-5,167-1,0410000000
   Accumulated Other Comprehensive Income 
0
-560
-465
0
0
222
1,607
451
468
204
179
-363
-764
-1,340
-110
413
655
397
794
794397655413-110-1,340-764-3631792044684511,60722200-465-5600
   Capital Surplus 
0
0
0
0
0
0
0
142,923
146,199
158,480
465,272
467,940
473,796
478,033
0
492,475
490,598
0
0
00490,598492,4750478,033473,796467,940465,272158,480146,199142,9230000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
0
284,837
3,309
0
0
2,342
287,092
142,923
146,199
158,480
465,272
467,940
473,796
478,033
481,919
492,475
490,598
492,493
494,254
494,254492,493490,598492,475481,919478,033473,796467,940465,272158,480146,199142,923287,0922,342003,309284,8370



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue512,345
Cost of Revenue-192,994
Gross Profit319,351319,351
 
Operating Income (+$)
Gross Profit319,351
Operating Expense-303,340
Operating Income16,01116,011
 
Operating Expense (+$)
Research Development13,446
Selling General Administrative303,429
Selling And Marketing Expenses0
Operating Expense303,340316,875
 
Net Interest Income (+$)
Interest Income0
Interest Expense-40,676
Other Finance Cost-10,883
Net Interest Income-51,559
 
Pretax Income (+$)
Operating Income16,011
Net Interest Income-51,559
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-121,111153,133
EBIT - interestExpense = -24,665
-156,145
-115,554
Interest Expense40,676
Earnings Before Interest and Taxes (EBIT)16,011-80,435
Earnings Before Interest and Taxes (EBITDA)73,376
 
After tax Income (+$)
Income Before Tax-121,111
Tax Provision--16,262
Net Income From Continuing Ops-203,757-104,849
Net Income-156,230
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses496,334
Total Other Income/Expenses Net-137,12251,559
 

Technical Analysis of Bioventus
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Bioventus. The general trend of Bioventus is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Bioventus's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Bioventus Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.93 < 5.28 < 5.85.

The bearish price targets are: 4.3 > 4.3 > 4.28.

Tweet this
Bioventus Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Bioventus Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Bioventus Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Bioventus Inc.

Bioventus Inc Daily Moving Average Convergence/Divergence (MACD) ChartBioventus Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Bioventus Inc. The current adx is .

Bioventus Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Bioventus Inc.

Bioventus Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Bioventus Inc.

Bioventus Inc Daily Relative Strength Index (RSI) ChartBioventus Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Bioventus Inc.

Bioventus Inc Daily Stochastic Oscillator ChartBioventus Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Bioventus Inc.

Bioventus Inc Daily Commodity Channel Index (CCI) ChartBioventus Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Bioventus Inc.

Bioventus Inc Daily Chande Momentum Oscillator (CMO) ChartBioventus Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Bioventus Inc.

Bioventus Inc Daily Williams %R ChartBioventus Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Bioventus Inc.

Bioventus Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Bioventus Inc.

Bioventus Inc Daily Average True Range (ATR) ChartBioventus Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Bioventus Inc.

Bioventus Inc Daily On-Balance Volume (OBV) ChartBioventus Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Bioventus Inc.

Bioventus Inc Daily Money Flow Index (MFI) ChartBioventus Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Bioventus Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-07ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Bioventus Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Bioventus Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose4.550
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Bioventus with someone you think should read this too:
  • Are you bullish or bearish on Bioventus? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Bioventus? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Bioventus Inc

I send you an email if I find something interesting about Bioventus Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Bioventus Inc.

Receive notifications about Bioventus Inc in your mailbox!